复发缓解型多发性硬化患者萎缩性T2病灶体积与残疾进展的10年连续随访研究
研究纳入176例复发缓解型多发性硬化患者,基线与6个月及此后每年行MR检查共10年,用基线病灶掩膜与随访CSF部分容积图计算萎缩性T2病灶体积。该指标在头6个月即可区分稳定组与确认残疾进展组(差异140%,Cohen d=0.54,P=.004),Cox回归中0-6个月(HR=4.23,P=.04)和0-12个月(HR=2.41,P=.022)是唯一显著的MR预测因子。
要点
- 萎缩性T2病灶体积在头6个月即可区分稳定组与残疾进展组(差异140%,P=.004)。
- 0-6个月HR=4.23、0-12个月HR=2.41,是唯一显著预测残疾进展时间的MR指标。
- 加入该指标后层级模型R²=0.27、R²变化0.11(P=.009),优于其他MR指标。
核心结论
- 萎缩性T2病灶体积是复发缓解型多发性硬化残疾进展的稳健且早期标志物。
研究设计与样本
- 10年连续随访研究,176例复发缓解型多发性硬化患者,基线、6个月及此后每年行MR检查;以48周后确认的10年确认残疾进展为参考标准,分稳定组(n=76)与确认残疾进展组(n=100)。
关键影像表现/征象
- T2病灶消失进入脑脊液间隙在MS患者中常见,萎缩性T2病灶体积由基线病灶掩膜与随访CSF部分容积图结合计算。
诊断标准与关键数值
- 稳定组与确认残疾进展组在头6个月即出现萎缩性T2病灶体积分离(差异140%,Cohen d=0.54,P=.004),并在所有时间点保持显著(P≤.007)。
- 层级模型纳入10年所有其他MR结局后,加入萎缩性T2病灶体积使R²=0.27、R²变化0.11(P=.009)。
- Cox回归中萎缩性T2病灶体积0-6个月(HR=4.23,P=.04)与0-12个月(HR=2.41,P=.022)是唯一显著预测确认残疾进展时间的MR指标。
临床应用与阅片要点
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND AND PURPOSE: Disappearance of T2 lesions into CSF spaces is frequently observed in patients with MS. Our aim was to investigate temporal changes of cumulative atrophied brain T2 lesion volume and 10-year confirmed disability progression.
MATERIALS AND METHODS: We studied 176 patients with relapsing-remitting MS who underwent MR imaging at baseline, 6 months, and then yearly for 10 years. Occurrence of new/enlarging T2 lesions, changes in T2 lesion volume, and whole-brain, cortical and ventricle volumes were assessed yearly between baseline and 10 years. Atrophied T2 lesion volume was calculated by combining baseline lesion masks with follow-up CSF partial volume maps. Ten-year confirmed disability progression was confirmed after 48 weeks. ANCOVA detected MR imaging outcome differences in stable (n = 76) and confirmed disability progression (n = 100) groups at different time points; hierarchic regression determined the unique additive variance explained by atrophied T2 lesion volume regarding the association with confirmed disability progression, in addition to other MR imaging metrics. Cox regression investigated the association of early MR imaging outcome changes and time to development of confirmed disability progression.
RESULTS: The separation of stable-versus-confirmed disability progression groups became significant even in the first 6 months for atrophied T2 lesion volume (140% difference, Cohen d = 0.54, P = .004) and remained significant across all time points (P ≤ .007). The hierarchic model, including all other MR imaging outcomes during 10 years predicting confirmed disability progression, improved significantly after adding atrophied T2 lesion volume (R 2 = 0.27, R 2 change 0.11, P = .009). In Cox regression, atrophied T2 lesion volume in 0-6 months (hazard ratio = 4.23, P = .04) and 0-12 months (hazard ratio = 2.41, P = .022) was the only significant MR imaging predictor of time to confirmed disability progression.
CONCLUSIONS: Atrophied T2 lesion volume is a robust and early marker of disability progression in relapsing-remitting MS.
引用
- Zivadinov R, Horakova D, Bergsland N, et al. A Serial 10-Year Follow-Up Study of Atrophied Brain Lesion Volume and Disability Progression in Patients with Relapsing-Remitting MS. AJNR Am J Neuroradiol. 2019. PMID: 30819766. doi:10.3174/ajnr.A5987
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。